Fortress Biotech (DB:CNB1) - Cotización, noticias y análisis

Resumen de acción CNB1

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States.

Acerca de la empresa

CNB1 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	5/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Cotiza un 96.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 55.31%

Análisis de riesgos

Tiene menos de 1 año de cash runway

Patrimonio neto negativo

Los accionistas han sido diluidos sustancialmente en el último año

Acciones altamente ilíquidas

+ 1 riesgos adicionales

Competidores de Fortress Biotech, Inc.

Medigene

XTRA:MDG1

€37.0m

Heidelberg Pharma

XTRA:HPHA

€138.4m

2invest

XTRA:2INV

€50.6m

co.don

XTRA:CNW

€6.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Fortress Biotech
Historical stock prices
Current Share Price	US$4.13
52 Week High	US$15.04
52 Week Low	US$3.66
Beta	2.04
1 Month Change	0%
3 Month Change	-3.03%
1 Year Change	-63.88%
3 Year Change	-89.65%
5 Year Change	-73.00%
Change since IPO	-96.61%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	CNB1	DE Biotechs	Mercado DE
7D	0%	0.8%	1.2%
1Y	-63.9%	-24.4%	2.0%

Rentabilidad vs. Industria: CNB1 obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -21.1%.

Rentabilidad vs. Mercado: CNB1 obtuvo unos resultados inferiores a los del mercado German, que fue del -0.3% el año pasado.

Volatilidad de los precios

Is CNB1's price volatile compared to industry and market?
CNB1 volatility
CNB1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.1%
10% least volatile stocks in DE Market	2.5%

Precio estable de las acciones: CNB1 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de CNB1 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2006	187	Lindsay Rosenwald	www.fortressbiotech.com

Resumen de fundamentos de Fortress Biotech, Inc.

¿Cómo se comparan los beneficios e ingresos de Fortress Biotech con su capitalización de mercado?
Estadísticas fundamentales de CNB1
Capitalización bursátil	€40.65m
Beneficios(TTM)	-€71.57m
Ingresos (TTM)	€56.64m

0.7x

Ratio precio-ventas (PS)

-0.6x

Ratio precio-beneficio (PE)

¿Está CNB1 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CNB1
Ingresos	US$61.97m
Coste de los ingresos	US$155.48m
Beneficio bruto	-US$93.51m
Otros gastos	-US$15.20m
Beneficios	-US$78.31m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-4.26
Margen bruto	-150.89%
Margen de beneficio neto	-126.36%
Ratio deuda/patrimonio	-397.1%

¿Cómo se ha desempeñado CNB1 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CNB1

Recompensas

Análisis de riesgos

Competidores de Fortress Biotech, Inc.

XTRA:MDG1

€37.0m

XTRA:HPHA

€138.4m

XTRA:2INV

€50.6m

XTRA:CNW

€6.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Recent updates

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Fortress Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $11 million.

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

New major risk - Financial position

Second quarter 2023 earnings released: US$0.24 loss per share (vs US$0.24 loss in 2Q 2022)

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.18 loss in 1Q 2022)

Fortress Biotech Receives Second 180-Calendar Day Grace Period from Nasdaq to Regain Compliance with the Nasdaq Listing Rule 5550(a)(2)

Full year 2022 earnings released: US$0.97 loss per share (vs US$0.79 loss in FY 2021)

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $13.896816 million.

Fortress Biotech, Inc. Appoints Lucy Lu, M.D., to Its Board of Directors

Executive Chairman recently bought €65k worth of stock

No longer forecast to breakeven

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.26 loss in 3Q 2021)

Insufficient new directors

Fortress Biotech Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Executive Chairman recently bought €71k worth of stock

Urica Therapeutics, Inc Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.044 loss in 2Q 2021)

Fortress Biotech, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Fortress Biotech Inc. Appoints David Jin as Chief Financial Officer

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 2000 Dynamic Index

Fortress Biotech, Inc.'s Subsidiary UR-1 Therapeutics, Inc. Doses First Patient in a Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Gout in the United States

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2021)

Fortress Biotech, Inc. to Report Q1, 2022 Results on May 10, 2022

Fortress Biotech, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Forecast breakeven date pushed back to 2024

Fortress Biotech, Inc. Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV

Third quarter 2021 earnings released: US$0.26 loss per share (vs US$0.20 loss in 3Q 2020)

Forecast to breakeven in 2022

Second quarter 2021 earnings released: US$0.044 loss per share (vs US$0.19 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.20 loss in 1Q 2020)

Forecast to breakeven in 2024

Fortress Biotech, Inc. Provides Sales Guidance for the Year 2021

New 90-day high: €3.76

New 90-day high: €3.04

New 90-day high: €2.96

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fortress Biotech, Inc. (FBIO)

Fortress Biotech Announces Breakthrough Therapy Designation for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease

Pomerantz Law Firm Announces the Filing of A Class Action Against Fortress Biotech, Inc. Certain Officers

Third quarter 2020 earnings released: US$0.20 loss per share

Revenue misses expectations

New 90-day low: €2.16

CFO, Treasurer & Corporate Secretary recently sold €106k worth of stock

New 90-day high - €3.48

New 90-day high - €3.00

First half earnings released

New 90-day high - €2.88

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Fortress Biotech, Inc.

0.7x

-0.6x

Beneficios e Ingresos